Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

115.44 +2.12 (+1.88%)
Delayed Quote Updated: 1:33 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
29 30 Next >
News headline image
The Analyst Verdict: Incyte In The Eyes Of 15 Experts ↗
 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Via ACCESSWIRE
News headline image
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
Via ACCESSWIRE
News headline image
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
Via ACCESSWIRE
News headline image
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer ↗
Via The Motley Fool
News headline image
Cracking The Code: Understanding Analyst Reviews For Incyte ↗
 
Via Benzinga
News headline image
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio? ↗
Large-cap stocks had a rough week, including Target, PDD Holdings, ZTO Express, Tenet Healthcare, Ulta Beauty, Intuit, Nokia, Alibaba, Santander, and Incyte. 
Via Benzinga
News headline image
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review ↗
Many leaders flashed buy signals. Bitcoin raced toward $100,000. 
Via Investor's Business Daily
News headline image
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Reverses Losses Amid Nvidia Fanfare ↗
Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine. 
Via Talk Markets
News headline image
Gold Moves Higher; Medtronic Posts Upbeat Results ↗
 
Via Benzinga
News headline image
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday? ↗
Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the ongoing Russia-Ukraine conflict. 
Via Benzinga
Topics Energy
News headline image
What's Going On With Incyte Shares Tuesday? ↗
Incyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development. 
Via Benzinga
News headline image
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges ↗
Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations. 
Via Benzinga
News headline image
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views ↗
 
Via Benzinga
Topics Earnings
News headline image
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. ↗
The company is discontinuing development of one drug and pausing enrollment in the study of another. 
Via Investor's Business Daily
News headline image
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.